Efficacy and Safety Analysis of Sindilizumab Assisted GP Chemotherapy in the Treatment of Senile Advanced Non-Small Cell Lung Cancer
Objective To analyze the effect of Sindilizumab assisted GP chemotherapy in elderly patients with advanced non-small cell lung cancer(NSCLC).Methods 60 elderly patients with advanced NSCLC admitted to our hospital from March 2022 to May 2023 were selected and divided into a control group and an observation group with 30 cases in each group according to random number table method.The control group was treated with GP chemotherapy,and the observation group was treated with sindillizumab on the basis of the control group.The treatment lasted for 3 courses at 21 days.The clinical efficacy,tumor markers,immune function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.33%,higher than 73.33%of the control group,the difference was statistically significant(P＜0.05).After treatment,the carcinoembryonic antigen of the observation group was(4.51±1.26)ng/mL,carbohydrate antigen 242 was(26.59±2.53)U/mL,carbohydrate antigen 199 was(38.52±4.19)U/mL,and CD8+ was(27.35±2.22)%,they were lower than(7.25±1.63)ng/mL,(34.21±3.25)U/mL,(43.46±5.25)U/mL,(33.59±3.61)%in control group,and the differences between groups were statistically significant(P＜0.05);the CD3+ of the observation group was(68.97±6.71)%,CD4+ was(38.75±3.46)%,higher than(54.25±5.69)%,(30.21±2.40)%of control group,the differences between groups were statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sindilizumab assisted GP chemotherapy regimen can reduce the level of tumor markers in elderly patients with advanced NSCLC and protect immune function without serious adverse reactions,so it can be applied.
NETL
NSTL
万方数据
